{"drugs":["Alglucerase","Ceredase"],"mono":{"0":{"id":"15240-s-0","title":"Generic Names","mono":"Alglucerase"},"1":{"id":"15240-s-1","title":"Dosing and Indications","sub":{"0":{"id":"15240-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Non-neuropathic Gaucher's disease, chronic, symptomatic:<\/b> initial, individualized dose (based on disease severity) IV over 1 to 2 h, dose range: 2.5 units\/kg IV 3 times weekly to 60 units\/kg IV every 1 to 4 wks; usual dosage: 60 units\/kg IV every 2 wks<\/li><li><b>Non-neuropathic Gaucher's disease, chronic, symptomatic:<\/b> maintenance, may attempt reducing dosage at 3 to 6 mo intervals after patient response is established<\/li><\/ul>"},"1":{"id":"15240-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Non-neuropathic Gaucher's disease, chronic, symptomatic:<\/b> initial, individualized dose (based on disease severity) IV over 1 to 2 h, dose range: 2.5 units\/kg IV 3 times weekly to 60 units\/kg IV every 1 to 4 wks; usual dosage: 60 units\/kg IV every 2 wks<\/li><li><b>Non-neuropathic Gaucher's disease, chronic, symptomatic:<\/b> maintenance, may attempt reducing dosage at 3 to 6 mo intervals after patient response is established<\/li><\/ul>"},"3":{"id":"15240-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Non-neuropathic Gaucher's disease, chronic, symptomatic<br\/>"}}},"3":{"id":"15240-s-3","title":"Contraindications\/Warnings","sub":[{"id":"15240-s-3-9","title":"Contraindications","mono":"hypersensitivity to alglucerase products<br\/>"},{"id":"15240-s-3-10","title":"Precautions","mono":"<ul><li>alglucerase may be excreted in human milk<\/li><li>discontinue if signs of hypersensitivity develops<\/li><li>presence of androgen-sensitive malignancies; use with caution in prepubertal boys<\/li><li>alglucerase is derived from pooled human placental tissue and may contain viable viruses; risk of contamination is believed to be remote<\/li><\/ul>"},{"id":"15240-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"15240-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"15240-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Swelling at injection site<\/li><li><b>Endocrine metabolic:<\/b>Shivering<\/li><li><b>Gastrointestinal:<\/b>Abdominal discomfort, Nausea, Vomiting<\/li><li><b>Neurologic:<\/b>Pain<\/li><li><b>Other:<\/b>Burning sensation, Fever<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Anaphylaxis (rare)<br\/>"},"6":{"id":"15240-s-6","title":"Drug Name Info","sub":{"0":{"id":"15240-s-6-17","title":"US Trade Names","mono":"Ceredase<br\/>"},"2":{"id":"15240-s-6-19","title":"Class","mono":"<ul><li>Enzyme<\/li><li>Gastrointestinal Agent<\/li><\/ul>"},"3":{"id":"15240-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"15240-s-7","title":"Mechanism Of Action","mono":"Systemic: Alglucerase catalyzes the hydrolysis of the glycolipid glucocerebroside to glucose and ceramide as part of the normal degradation pathway for membrane lipids.  <br\/>"},"8":{"id":"15240-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"15240-s-8-24","title":"Distribution","mono":"Systemic: Vd: 49.4 to 282.1 mL\/kg <br\/>"},"4":{"id":"15240-s-8-27","title":"Elimination Half Life","mono":"Systemic: 3.6 to 10.4 minutes <br\/>"}}},"9":{"id":"15240-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>should be filtered with an in-line particulate filter during infusion<\/li><li>do not shake solutions (may denature and inactivate the glycoprotein)<\/li><li>dilute with NS to a maximum final volume of 200 mL and infuse over 1 to 2 hrs<\/li><li>stable for up to 18 h after final dilution when store under refrigeration at 2 to 8 degrees Celsius (C)<\/li><\/ul>"},"10":{"id":"15240-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement<\/li><li>hematologic parameters, including hemoglobin, hematocrit, erythrocyte and platelet counts<\/li><li>IgG antibody formation<\/li><li>serum tryptase levels and complement activation; within 2 hours of developing hypersensitivity symptoms<\/li><\/ul>"},"13":{"id":"15240-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug is derived from pooled human placental tissue and may carry a remote risk of transmitting infectious agents. Risks and benefits should be discussed with patient by healthcare professional.<\/li><li>This drug may cause shivering, abdominal discomfort, nausea, vomiting, pain, burning sensation, or fever.<\/li><\/ul>"}}}